Article Index

biotech stocks

Google's Larry Page and Sergey Brin Plan to Cure Aging with Biotech Venture

Larry Page and Sergey Brin

Google Inc.'s (Nasdaq: GOOG, GOOGL) Larry Page and Sergey Brin have taken anti-aging to a whole new level.

In 2013, Google founded the biotech company Calico along with Apple Inc. (Nasdaq: AAPL) Chairman Arthur Levinson.

Rather than focusing on diseases, Calico was founded to cure aging. According to Page, expanding the human life span by as much as 100 years is the company's goal.

Thanks to new breakthroughs, they may be closer than you think...

The Next Great Blockbuster Biotech Stock to Buy Now

biotech stock

Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.

That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.

Now, Money Morning Biotech Investing Specialist Ernie Tremblay has found a new biotech stock to buy that could be the next cancer blockbuster...

These Promising Cancer Therapies Are a Biotech "Triple Play"

biotech

On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.

Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.

And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.

It's clear that investors can do very well with the right cancer drug.

But there, of course, is the rub: Finding the right cancer drug is not so easy.

I'm about to show you three companies - all sound investments - running strong in the race to fight this scourge, and the one that could very well take the prize...

The Best Biotech ETF to Buy in 2015

Biotech etf

Biotech stocks have seriously outperformed the markets in 2015, and our favorite biotech ETF has been one of the biggest winners.

In the last year, the Nasdaq Biotechnology Index has soared 48.3%. The Dow and S&P 500 are up just 7.3% and 8.6% in that time.

Here's our favorite biotech ETF to buy now...

How to Play Organovo (NYSE: ONVO) Stock After Earnings

ONVO stock

Organovo Holdings Inc. (NYSE: ONVO) stock is up 12.7% this week after the company reported quarterly and fiscal year earnings on Tuesday.

For the quarter ending March 31, ONVO reported an earnings per share (EPS) loss of $0.10. That was below the consensus estimate of a $0.09 loss.

Here's what else investors need to know about ONVO stock now...

Top Biotechnology Companies Profiting from ASCO 2015

biotechnology companies

The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago this week.

More than 30,000 people attend the event, which features more than 4,000 presentations from some of the top biotechnology companies in the world.

For investors, this provides us an in-depth look at some of the world’s best biotechnology companies to invest in.

Why Organovo Stock Is a Top Biotech Stock to Buy in 2015

Organovo stock

One of our favorite biotech stocks of 2015, Organovo stock, has climbed 41% since the end of March. And that's just the start for this revolutionary biotech investment.

You see, Organovo Holdings Inc. (NYSEMKT: ONVO) is part of one of the most exciting biotech industries on the market. It's called 3D bioprinting, and the applications are huge.

Here's a closer look at the 3D bioprinting market and why it's providing us with such a great investment opportunity.

"21st Century Cures" Could Revolutionize Biotech

Medicine Pills Stacked Like Increasing Graph on Newly Designed U.S. One Hundred Dollar Bills.

No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

But new regulations on the table could change everything for biotech investors and critically ill patients...

How You Made 53% in Two Months with This Biotech Stock

Biotech Stock

We first recommended this incredible biotech stock in 2013. It's since realized a growth of 342%.

And better yet: it's expected to continue growing at an exponential rate.

Here's why you should add stellar security to your portfolio...

This Top Biotech Stock Just Got a $100 Billion "Buy" Signal

Global cancer spending topped $100 billion for the first time after climbing a whopping 10% in 2014.

And that's a major "buy" signal for one of the top biotech stock picks we've been recommending at Money Morning.

According to a report from the IMS Institute of Health, rising drug prices and increased incidence of cancer led to the 10% spike in drug spending last year.

Here's what that means for our top investment...

Biotech Investing for Beginners: Your 7-Step Guide

Biotech news

Biotech investing can be tricky. The industry is complicated, and the stocks are volatile.

But the profit payoff can be life-changing.

That's why we've created the "Biotech Investing for Beginners Guide" with Money Morning's Biotech Investing Specialist Ernie Tremblay.

That's because many of the metrics we use to evaluate other stocks - like P/E ratio, profit margin, earnings per share - don't always apply to biotech stocks.

Here's Tremblay's step-by-step guide to investing in biotech stocks...

Two Divergent Northbound Stocks to Buy Right Now

biotech

I want to spend today talking to you about two stocks that we've repeatedly recommended to Private Briefing readers.

Both stocks made bullish headlines last week.

One of the stocks is a winner - a big winner, in fact. And the other has been a loser - so far.

But we're predicting it will be a big winner, too - a huge winner.

And last week's developments strengthened our case...

2015 Top Stock Picks: AMBA, SWKS, RMBS

market volatility

Our Money Morning 2015 top stock picks have seen biotech hit a snag.

But in that time, semiconductor tech stocks have been up big - as much as 45% for one name.

Here's how the big chipmaker tech stocks are doing, as well as some of our other 2015 top stock picks...

The 3 Best Biotech Stocks to Buy at Today's Discounted Prices

Best biotech stocks

The biotech market has sold off last week, with the Nasdaq Biotechnology Index dropping 6.4% since April 23. And because of that, some of the best biotech stocks have dipped as well.

Now, investors are wondering if they should take their money to the sideline. But Money Morning's Bioscience Investing specialist Ernie Tremblay says this type of move is normal for the biotech market.

Here are three stocks we're recommending now that they're trading at discounted prices...

2015 Top Stock Picks: PRTA, AMBA, RMBS

If you’ve been following our Money Morning 2015 top stock picks, you may notice a big shakeup from last week.

That’s right, some of the best biotech stock to buy right now are only up somewhere between 30% and 50%.

Here’s why this sell-off isn’t going to rain on biotech’s parade…

© 2015 Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201, Email: customerservice@MoneyMorning.com